[PHARMACOLOGY OF 2-BENZENESULFONAMIDO-5-(2-METHOXYETHOXY)-PYRIMIDINE (GLYCODIAZIN), A NEW BLOOD SUGAR-LOWERING COMPOUND].
D000315:Adrenalectomy; D000818:Animals; D035843:Biomedical Research; D001786:Blood Glucose; D002626:Chemistry, Pharmaceutical; D003921:Diabetes Mellitus, Experimental; D004285:Dogs; D007004:Hypoglycemic Agents; D051379:Mice; D010600:Pharmacology; D011743:Pyrimidines; D011817:Rabbits; D051381:Rats; D012106:Research; D000077145:Sulfanilamide; D013424:Sulfanilamides; D013449:Sulfonamides
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D011743:Pyrimidines; D013424:Sulfanilamides; D013449:Sulfonamides; D000077145:Sulfanilamide; C030986:pyrimidine
ADRENALECTOMY; ALLOXAN DIABETES; ANTIDIABETICS; CHEMISTRY, PHARMACEUTICAL; CLINICAL RESEARCH; DOGS; EXPERIMENTAL LAB STUDY; MICE; PHARMACOLOGY; PYRIMIDINES; RABBITS; RATS; SULFONAMIDES
PHARMAKOLOGIE DES 2-BENZOLSULFONAMIDO-5(BETA-METHOXY-AETHOXY)-PYRIMIDINS (GLYCODIAZIN), EINER NEUEN BLUTZUCKERSENKENDEN VERBINDUNG.